Antiinflammatory and immunomodulatory properties of statins

Immunologic Research

Volumn 25, Issue 3, 2002, Pages 271-285

  Shovman, Ora ^a   Levy, Yair ^a   Gilburd, Boris ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atherosclerosis; Endothelial cells; Immune system; Inflammation; Lymphocytes; Monocytes; Smooth Muscle cells; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL FUNCTION; CELL METABOLISM; CHEMOTAXIS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTES; MICE; MONOCYTES; MUSCLE, SMOOTH; RABBITS;

EID: 0036235053     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:25:3:271     Document Type: Review

References (132)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
8. Cholesterol management in theory and practice
9. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram
10. Atherosclerosis - An inflammatory disease
11. Inflammatory and immune aspects of atherosclerosis
12. Chlamydia in coronary plaques - Hidden culprit or harmless hobo?
13. Infectious agents and atherosclerotic vascular disease
14. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
15. Atherosclerosis as an infectious, inflammatory and autoimmune disease
16. Is atherosclerosis an immunologically mediated disease?
17. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis
18. Reactivity of peripheral blood lymphocytes to oxidized low-density lipoprotein: A novel system to estimate atherosclerosis employing the Cellscan
19. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty
20. Autoantibodies to oxidized low-density lipoprotein in coronary artery disease
21. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis
22. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis
23. Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis
24. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65
25. Autoantibodies associated with atherosclerosis
26. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression
27. The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis
28. The prediction of coronary atherosclerosis employing artificial neural networks
29. The anti-phospholipid (Hughes) syndrome: A crossroads of autoimmunity and atherosclerosis
30. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I
31. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice
32. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice
33. Beta 2-glycoprotein I in human and murine atherosclerosis
34. Monocytes from patients with combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia show an increased adhesion to endothelial cells in vitro: II. Influence of intrinsic and extrinsic factors on monocyte binding
35. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
36. Integrin mediated adhesion of mononuclear cells from patients with familial hypercholesterolemia
37. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia
38. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions
39. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
40. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
41. Functionally abnormal monocytes in hypercholesterolemia
42. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
43. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and in vivo studies
44. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
45. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits
46. Lovastatin induces differentiation of Mono Mac 6 cells
47. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease
48. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins - Consequences for plasmin generation and monocyte adhesion
49. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - A possible protective mechanism against atherothrombosis
50. Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products
51. In vivo properties of monocyte chemoattractant protein-1
52. Chemokines and atherosclerosis
53. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody
54. Cytokine regulation of endothelial cell function: From molecular level to the bed side
55. Inhibition of monocyte chemotactic protein-1 synthesis by statins
56. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin
57. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats
58. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
59. Upregulation of endothelial nitric oxide synthase by HMGCoA reductase inhibitors
60. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPas
61. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - The relevance of endothelial nitric oxide synthase and superoxide anion scavenging action
62. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering
63. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques
64. The distribution of adhesion molecules in human atherosclerosis
65. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis
66. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide
67. Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload
68. Effects of simvastatin treatment on s1CAM-1 and sE-selectin levels in hypercholesterolemic subjects
69. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages
70. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions
71. Oxidatively modified low density lipoprotein is a chemoreactant for human T lymphocytes
72. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells
73. Cell proliferation in human coronary arteries
74. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits
75. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques
76. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits
77. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures
78. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells
79. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages
80. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF
81. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
82. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
83. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis
84. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
85. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
86. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
87. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
88. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
89. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
90. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits
91. Direct effects of statins on the vascular wall
92. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
93. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress
94. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
95. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
96. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme
97. The smooth muscle cell: Sinner or saint in restenosis and the acute coronary syndromes?
98. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: Local collagen loss as a prerequisite of plaque rupture
99. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal
100. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
101. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
102. Pro-apoptotic effect of fluvastatin on human smooth muscle cells
103. Sterol metabolism and lymphocyte responsiveness: Inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation
104. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin
105. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro
106. Statins as a newly recognized type of immunomodulator
107. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA
108. Immunomodulation: A new role for statins?
109. Inhibition of proinflammatory cytokine production by pravastatin
110. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro
111. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
112. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
113. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
114. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells
115. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
116. Protein lipidation in cell signaling
117. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s)
118. Effect of pravastatin on outcomes after cardiac transplantation
119. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
120. HMG-CoA reductase inhibition by atorvastatin redues neointimal inflammation in a rabbit model of atherosclerosis
121. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
122. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
123. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
124. Long-term effects of pravastatin on plasma concentration of C-reactive protein
125. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
126. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
127. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression
128. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
129. Are there potential non-lipid-lowering uses of statins?
130. Carcinogenicity of lipid-lowering drugs
131. Do statins cause cancer? A meta-analysis of large randomized clinical trials
132. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men